Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study


Source: Annual Congress 2002 - Combination therapies in asthma and COPD
Session: Combination therapies in asthma and COPD
Session type: Poster Discussion
Number: 2406
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study. Eur Respir J 2002; 20: Suppl. 38, 2406

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001

Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial)
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004

Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up
Source: Eur Respir J 2005; 26: Suppl. 49, 369s
Year: 2005

Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design
Source: Eur Respir J 2003; 22: Suppl. 45, 534s
Year: 2003

Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo
Source: Eur Respir J 2006; 28: Suppl. 50, 764s
Year: 2006

Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015